Verify current applicability of this policy with Aetna, as the review date (2026-09-25) indicates this is an active policy but no specific effective date for changes is stated in the source material. Billing team should: (1) Confirm whether this CPB 0634 review resulted in coverage or documentation changes from the prior version; (2) Audit current authorizations and denials for mini-allograft procedures using the listed CPT/HCPCS codes (38204–38215, 38230, 38240, 38242, S2150) to ensure they align with the stated medical necessity indications (ALL, AML, aplastic anemia, CLL, CML, Hodgkin's disease, multiple myeloma, myelofibrosis, myelodysplasia, neuroblastoma, NHL, sickle cell anemia, thalassemia major); (3) Confirm that procedures for experimental indications (breast cancer, melanoma, ovarian cancer, renal cancer, testicular cancer, autoimmune diseases, essential thrombocythemia, polycythemia vera, acquired angioedema) are being flagged for prior authorization review or denial per policy; (4) Review related CPB policies (0494, 0495, 0496, 0497, 0507, 0606, 0617, 0626, 0627, 0635, 0640, 0674, 0811, 0836, 0838) to verify coordination of mini-allograft coverage across disease-specific policies.